Struggling Tokai Pharma Nixes Enrollment in Mid-Stage Prostate Cancer Study
Nano cap Tokai Pharmaceuticals (NASDAQ:TKAI) hits the skids again with lead product candidate galeterone. Today, the company disclosed that it has terminated enrollment in its Phase 2 expansion clinical trial, ARMOR2, assessing galeterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have become resistant to Medivation's (NASDAQ:MDVN) Xtandi (enzalutamide).
It has also decided not to proceed with its planned study of galeterone in mCRPC patients who rapidly progress on either Xtandi or Janssen's (NYSE:JNJ) Zytiga (abiraterone acetate).
It has also decided not to proceed with its planned study of galeterone in mCRPC patients who rapidly progress on either Xtandi or Janssen's (NYSE:JNJ) Zytiga (abiraterone acetate).